David Roth, MD of Syros Pharmaceuticals describes his company’s gene control methodology to target genetic conditions in a unique way. Instead of the more traditional gene therapies that are the focus of many studies, Syros investigates and identifies disease-causing alterations in gene expression to create medicines that control the expression of genes.
The company currently has medicines in clinical trials to treat acute myeloid lymphoma (AML) as well as numerous medicines in pre-clinical develop to treat sickle cell disease, myeloproliferative neoplasms, and other cancers.
For more information, visit www.syros.com/
